Compass Pathways Reports Q2 Results, NDA Submission on Track for Q4 with Priority Voucher
CMPS has more than doubled off its 52-week low of $3.97.
Summary
Compass Pathways reported Q2 and first half 2026 financial results alongside business highlights. The company confirmed its rolling NDA submission for COMP360 in treatment-resistant depression remains on track for completion in Q4, with some modules already submitted. A National Priority Voucher was awarded, potentially accelerating FDA review to 1-2 months. A White House Executive Order directs the DEA to review psychedelic treatments that have completed Phase 3 trials, adding policy momentum. The update follows positive 26-week Phase 3 data reported in July and a cash runway into 2028. The combination of regulatory progress, policy support, and upcoming NDA completion positions the company for a potential approval catalyst in the near term.
At the time of this announcement, CMPS was trading at $11.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $3.97 to $15.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.